Expanding Product Portfolio Bertin Bioreagents offers an extensive catalog of over 20,000 product references, including innovative ELISA kits for specific biomarkers. This diversity provides opportunities to upsell or bundle new, specialized assays to existing clients engaged in metabolism, cardiovascular diseases, cancer, immunology, and inflammation research.

Recent Product Launches The recent introduction of sandwich-based ELISA kits for S100 proteins indicates a focus on developing tools for biomarker detection. Sales efforts can target laboratories focused on inflammation and immune response research, highlighting Bertin's commitment to cutting-edge bioanalytical solutions.

Market Focus and Research Applications With a strong emphasis on biomedical research areas such as cancer, cardiovascular health, and immunology, there is significant potential to tailor outreach to research institutions and pharma companies investing in these segments, emphasizing Bertin’s expertise and product relevance.

Financial Capacity With revenues ranging from $100 million to $1 billion, Bertin Bioreagents demonstrates robust market presence and purchasing power, enabling the development of strategic partnerships and volume-based sales approaches with higher-value client accounts.

Competitive Positioning Operating alongside industry peers like Enamine and Asinex, Bertin's focus on bioanalytical reagents and tools positions it as a specialized provider. Sales teams can leverage this niche focus by emphasizing product quality, customization, and research support to differentiate and grow market share.